Its role Owner
Millicent Pharma Limited is a privately held specialty pharmaceutical company specializing in women's health. Established in 2018 and headquartered in Dundalk, Ireland, the company focuses on the development, manufacturing, and commercialization of branded therapies for contraception, hormone replacement therapy, and related conditions.
Millicent operates integrated facilities including a manufacturing and R&D site in Larne, Northern Ireland, and a larger plant in Fajardo, Puerto Rico, acquired from Teva Pharmaceuticals and re-equipped for production of hormonal and non-hormonal products. Corporate functions are supported by offices in New Jersey, United States. The company maintains significant US commercial capabilities for nationwide product distribution.
Backed by The Carlyle Group and founded by experienced pharmaceutical executives, Millicent has built a portfolio including products such as Femlyv, Femring, and Intrarosa. It invests in internal R&D for novel therapeutics and enhanced dosage forms like orally disintegrating tablets and vaginal systems. The firm actively pursues acquisitions and partnerships to expand its offerings.
In the pharmaceutical industry, Millicent positions itself as a focused player in the women's health segment, leveraging its manufacturing expertise and global supply chain to deliver innovative treatments. Recent expansions include automation investments and job creation at its European sites, strengthening its operational footprint across Ireland, the United Kingdom, the United States, and Puerto Rico.
Also known as Millicent Pharma Ltd, Millicent Manufacturing PR, LLC, and Fajardo Millicent Pharmaceuticals.
chemXplore tracks 1 project involving Millicent Pharma, of which one is active.
active all projects
